Drugs / Phosphatidylserine-Omega3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00382616 | Jul 2004 → Jan 2005 | attention deficit-hyperactivity disorder | Tel-Aviv Sourasky Medical Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Phosphatidylserine-Omega3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00382616 ↗ |
| Known as | PS-Omega3 | “receive 250 mg/d of eicosapentaenoic acid + docosahexaenoic acid provided as phosphatidylserine (300 mg/d PS-Omega3), or fish oil or placebo for 3 months.” NCT00382616 ↗ |
| Modality | Other / unclassified | “EPA and DHA to phospholipid (PL-n-3)” PMID 18469236 ↗ May 2008 |